Systemic Hypertension

Systemic hypertension is the single most common cause of left ventricular hypertrophy encountered in everyday practice, and its echocardiographic picture overlaps genuinely — not just superficially — with hypertrophic cardiomyopathy and restrictive physiology. Telling these apart, and recognizing that a normal ejection fraction doesn’t mean normal systolic function in this population, are the two skills this page is built around.

Basic Principles

Hypertensive heart disease is an end-organ consequence of chronic pressure overload: sustained systemic hypertension drives LV hypertrophy to normalize wall stress. Diastolic function is impaired early, while systolic function (by conventional measures) initially remains normal. With long-standing disease, systolic dysfunction and ventricular dilation can eventually develop.

A concise list of typical echocardiographic findings is worth holding together as a constellation, since hypertensive heart disease rarely presents as an isolated finding:

• LV hypertrophy
• Diastolic dysfunction
• Ascending aortic dilation
• Aortic valve sclerosis
• Mitral annular calcification
• LA enlargement
• Atrial fibrillation

Classifying LV Geometry

LV geometry in hypertension is classified by combining LV mass index with relative wall thickness (RWT) into four categories:

	Normal RWT (under 0.42)	Increased RWT (≥0.42)
Normal LV mass	Normal geometry	Concentric remodeling
Increased LV mass	Eccentric hypertrophy	Concentric hypertrophy

Concentric hypertrophy is defined specifically as LV mass over 95 g/m² in women or 115 g/m² in men, combined with an RWT greater than 0.42. Concentric remodeling — increased RWT with normal mass — can represent an earlier stage; eccentric hypertrophy may be seen later in the disease course.

On standard imaging, hypertensive hypertrophy is classically symmetric — including the basal posterior wall, with an increased end-diastolic wall thickness (over 11 mm) — a genuinely useful distinguishing feature from hypertrophic cardiomyopathy, where the pattern is typically asymmetric. LV mass can be estimated from M-mode data assuming symmetric hypertrophy, but is preferably calculated from 2D data when hypertrophy is non-uniform.

A Genuinely Misleading Marker: Ejection Fraction

This is worth stating directly, since it’s easy to be reassured by a number that doesn’t reflect what’s actually happening at the myocardial level: LV systolic function by fractional shortening or ejection fraction is often normal or even increased in hypertension. These indices measure endocardial motion — chamber-level mechanics — not true myocardial mechanics.

LV midwall shortening, which more accurately reflects genuine sarcomeric shortening, is frequently reduced in hypertensive hypertrophy and concentric remodeling, even when EF looks entirely normal. The same pattern holds for deformation imaging: systolic annular tissue Doppler velocity (S′) and longitudinal strain are often reduced despite a normal or increased EF — and longitudinal strain abnormalities can appear even in prehypertension and early hypertension, before overt hypertrophy is established.

Circumferential and radial strain, by contrast, tend to be preserved — similar to what’s seen in athletes with physiologic hypertrophy — making longitudinal strain specifically the more sensitive marker for pathologic hypertensive change. Rotational indices (twist, rotation, torsion) are often normal or increased with preserved-to-increased EF, plausibly representing a compensatory mechanism for reduced longitudinal shortening — though torsion itself declines in the more advanced, eccentric-hypertrophy stage of disease.

Diastolic Dysfunction: Often the Earliest Finding

Diastolic dysfunction is typically the first echocardiographic abnormality in hypertensive heart disease, frequently preceding clear anatomic hypertrophy — worth actively screening for even when wall thickness still looks unremarkable. See LV Diastolic Function for the general grading framework (impaired relaxation, pseudonormal, and restrictive filling, grades I–III) that applies directly here.

The classic impaired relaxation pattern shows a prolonged isovolumic relaxation time, reduced and delayed E acceleration, a prolonged deceleration slope, an increased A velocity, and an E/A ratio under 1. With progression to LV systolic dysfunction, elevated LV end-diastolic and left atrial pressure produce pseudonormalization — an enhanced E velocity (from a higher mitral opening gradient) alongside a reduced A velocity. Coexisting mitral regurgitation can independently produce a “paradoxical” higher E velocity despite genuinely impaired relaxation, a confounder worth knowing when MR and hypertensive heart disease coexist — a common combination given mitral annular calcification’s own association with hypertension.

A genuinely useful differentiator from athletic remodeling: diastolic dysfunction is not seen in physiologic hypertrophy (“athlete’s heart”) even when wall thickness is clearly increased. In pathologic (hypertensive) hypertrophy, by contrast, diastolic dysfunction is often the first evidence of end-organ damage, genuinely useful when the distinction between physiologic and pathologic hypertrophy is otherwise unclear from wall thickness alone.

E/E′ independently predicts cardiovascular events in hypertensive populations without known cardiac disease — worth reporting explicitly given this prognostic weight, not just as a diastolic grading input.

A Distinctive and Genuinely Confusable Finding: Mid-Cavity Obliteration

In a small, hypertrophied, otherwise normally-contracting LV, mid-cavity obliteration can occur at end-systole, producing a brief, late-systolic, high-velocity Doppler signal — exacerbated by hypovolemia or increased contractility. This pattern is genuinely easy to mistake for hypertrophic cardiomyopathy, but three specific features distinguish it:

• The gradient’s duration is briefer than the LVOT gradient typically seen in HCM.
• The level of obstruction is mid-ventricular, not subaortic.
• Systolic anterior motion of the mitral valve is absent.

When this picture combines with normal-to-hyperdynamic systolic function, concentric hypertrophy, diastolic dysfunction, and this mid-ventricular late-systolic gradient, it has been termed “hypertensive hypertrophic cardiomyopathy” — worth knowing as a named pattern, though it’s explicitly not a true cardiomyopathy or an inherited disorder, simply severe end-organ damage from hypertension. Its genuine clinical value is in prompting consideration of hypertension as the explanation in a patient where HCM or restrictive cardiomyopathy might otherwise be suspected from the echo appearance alone.

Beyond the Ventricle: The Full Constellation

• Ascending aortic dilation, often with increased tortuosity of the ascending aorta, arch, and descending aorta, and increased irregular wall echogenicity reflecting atherosclerosis. The aortic annulus itself is not dilated in uncomplicated hypertension — a useful point when distinguishing hypertensive aortic change from other aortopathies.
• Aortic valve sclerosis, usually with mild aortic regurgitation.
• Mitral annular calcification, itself a cause of mild-to-moderate mitral regurgitation in this population.
• LA enlargement, from the combination of chronically elevated LV end-diastolic pressure and regurgitation — see Evaluation of the Left Atrium for the general assessment this finding fits into.

Arterial Stiffness: A Genuinely Underappreciated Contributor

Hypertension accelerates age-related arterial stiffness, which matters mechanically, not just as an incidental vascular finding: stiffer arteries increase the speed and magnitude of reflected pressure waves, which amplifies late systolic aortic pressure — directly increasing LV afterload — while widening pulse pressure and increasing pulsatile shear stress. This contributes directly to LV hypertrophy, diastolic dysfunction, and subendocardial ischemia, forming a genuine feedback loop between vascular and ventricular disease rather than two separate problems. Aortic strain and distensibility can be estimated from M-mode aortic diameter measurements, and ventricular-vascular coupling (the ratio of arterial to ventricular elastance) can be derived from 2D or 3D volumetric and pressure data — specialized measurements, but worth knowing as a genuine, quantifiable link between the vascular and ventricular consequences of hypertension.

Clinical Utility of Echocardiographic Assessment

LV mass is a strong, independent predictor of clinical outcome in hypertension. In patients with borderline hypertension specifically, an increased LV mass identifies a subgroup with genuinely worse prognosis even before other findings emerge. LV mass is argued to better reflect long-term hypertension severity than intermittent office blood pressure readings, since it represents temporally averaged pressure exposure rather than a single measurement — and tracking LV mass over time is a genuine way to assess the long-term effect of therapy.

When heart failure symptoms develop in a hypertensive patient, the distinction between diastolic and systolic dysfunction carries direct therapeutic implications, and echocardiography is central to making it — alongside screening for superimposed coronary or valvular disease rather than attributing every symptom to hypertension alone.

With long-standing disease, LV contractility can decline even without coexisting coronary disease — and systolic function does not always recover with aggressive antihypertensive therapy once dysfunction is established, suggesting genuinely irreversible changes in ventricular contractility in advanced cases. End-stage hypertensive heart disease can appear echocardiographically similar to end-stage dilated cardiomyopathy, worth keeping in mind when a patient’s clinical history includes long-standing, poorly controlled hypertension.

Whether routine echocardiographic screening is warranted in hypertension remains genuinely debated — most centers continue to rely on intermittent office blood pressure for medical management, reserving echocardiography for specific indications (symptom evaluation, risk stratification in borderline hypertension, or monitoring known hypertensive heart disease) rather than as a universal screening tool.

How to Approach the Hypertensive Patient: A Practical Sequence

1. Classify LV geometry explicitly using LV mass index and RWT together, rather than describing hypertrophy only qualitatively.
2. Don’t let a normal EF close the systolic function question — assess midwall shortening or longitudinal strain when the clinical picture suggests more impairment than EF alone implies.
3. Assess diastolic function carefully and early, since it often precedes visible hypertrophy — and use its presence or absence to help distinguish pathologic from physiologic hypertrophy when wall thickness alone is ambiguous.
4. Watch for mid-cavity obliteration in severely hypertrophied, hyperdynamic ventricles, and apply the three-feature checklist (gradient duration, obstruction level, absence of SAM) before considering HCM.
5. Screen the full constellation — aorta, aortic valve, mitral annulus, left atrium — rather than focusing solely on the ventricle.
6. Track LV mass serially when monitoring known hypertensive heart disease or therapy response, given its genuine prognostic and long-term-severity value beyond office blood pressure readings.
7. Consider the full differential — HCM, restrictive cardiomyopathy, and athletic remodeling — explicitly before settling on hypertensive heart disease as the explanation for a hypertrophied, diastolically abnormal ventricle.

Clinical Importance

Hypertensive heart disease rewards exactly the discipline this whole site has emphasized: a normal headline number (EF) can coexist with genuine myocardial dysfunction detectable by more sensitive measures, and a genuinely common condition can still closely mimic rarer, more feared diagnoses like HCM closely enough to warrant a deliberate, feature-by-feature differential rather than pattern-matching from wall thickness alone.